DeepMed Research

Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia

Phase 3

Completed

Conditions: Schizophrenia

Interventions: Drug: BI 425809
Drug: Placebo

First Posted Date: 2021-04-27

Last Posted Date: 2025-01-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 609

Registration Number: NCT04860830

Locations: 🇺🇸
Sunwise Clinical Research-Walnut Creek-70166, Walnut Creek, California, United States
🇺🇸
Synexus Clinical Research-Atlanta-67262, Atlanta, Georgia, United States
🇺🇸
Hassman Research Institute-Berlin-60540, Berlin, New Jersey, United States

and more 107 locations

Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)

Phase 3

Completed

Conditions: Schizophrenia

Interventions: Drug: Iclepertin
Drug: Placebo

First Posted Date: 2021-04-15

Last Posted Date: 2024-12-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 611

Registration Number: NCT04846881

Locations: 🇺🇸
Research in Miami Inc, Hialeah, Florida, United States
🇺🇸
Salem VA Medical Center, Salem, Virginia, United States
🇪🇸
Benito Menni Complejo Asistencial en Salud Mental, Sant Boi de Llobregat, Spain

and more 124 locations

Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1)

Phase 3

Completed

Conditions: Schizophrenia

Interventions: Drug: Iclepertin
Drug: Placebo

First Posted Date: 2021-04-15

Last Posted Date: 2024-11-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 620

Registration Number: NCT04846868

Locations: 🇧🇷
Hospital de Base - Fac Med de Sao Jose do Rio Preto, Sao Jose do Rio Preto, Brazil
🇧🇷
BR Trials, Sao Paulo, Brazil
🇬🇷
University General Hospital of Thessaloniki AHEPA, Thessaloniki, Greece

and more 113 locations

A Study to Find a Safe and Effective Dose of BI 1701963 Alone and in Combination With BI 3011441 in Patients With Advanced Cancer and a Certain Mutation (Kirsten Rat Sarcoma Viral Oncogene Homologue [KRAS])

Phase 1

Terminated

Conditions: Solid Tumors, KRAS Mutation

Interventions: Drug: BI 1701963
Drug: BI 3011441

First Posted Date: 2021-04-08

Last Posted Date: 2023-02-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 8

Registration Number: NCT04835714

Locations: 🇯🇵
National Cancer Center Hospital East, Chiba, Kashiwa, Japan
🇯🇵
National Cancer Center Hospital, Tokyo, Chuo-ku, Japan
🇯🇵
Aichi Cancer Center Hospital, Aichi, Nagoya, Japan

and more 1 locations

A Study to Test BI 767551 in People With Mild to Moderate Symptoms of COVID-19

Phase 2

Terminated

Conditions: COVID-19

Interventions: Drug: Placebo intravenous
Drug: BI 767551 intravenous
Drug: BI 767551 inhaled
Drug: Placebo inhaled

First Posted Date: 2021-03-30

Last Posted Date: 2022-07-28

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 5

Registration Number: NCT04822701

Locations: 🇺🇸
Ocean Blue Medical Research Center, Inc., Miami Springs, Florida, United States
🇺🇸
Advanced Surgeons and Physicians Network, Houston, Texas, United States
🇺🇸
Pharmatex Research, Amarillo, Texas, United States

and more 2 locations

A Study in Healthy People to Compare 3 Different Formulations of Apremilast Tablets Taken With or Without Food

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: EU-sourced Otezla®
Drug: US-sourced Otezla®
Drug: Japan-sourced Otezla®

First Posted Date: 2021-03-23

Last Posted Date: 2023-08-31

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 20

Registration Number: NCT04811573

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

A Study in Healthy Men to Test How Well Different Doses of BI 1819479 Are Tolerated and Taken up by the Body With or Without Food

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1819479
Drug: Placebo

First Posted Date: 2021-03-17

Last Posted Date: 2022-05-04

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 66

Registration Number: NCT04801693

Locations: 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

Proof of Concept Study Assessing Technology-Assisted Respiratory Adherence Prototype Version 3 in Individuals With COPD

Phase 2

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Device: TARA v3.2, both non-pharmacological and pharmacological self-management support
Device: TARA v3.1, only non-pharmacological self-management support

First Posted Date: 2021-03-12

Last Posted Date: 2023-12-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 5

Registration Number: NCT04795323

Locations: 🇺🇸
Clinical Research of Gastonia, Gastonia, North Carolina, United States
🇺🇸
Lowcountry Lung and Critical Care, Charleston, South Carolina, United States

Non-interventional Study for Real-world Data of Afatinib Treatment in First-line Setting and of Subsequent Therapies for Patients With Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-positive Lung Adenocarcinoma

Completed

Conditions: Non-squamous, Non-Small Cell Lung Cancer

Interventions: Drug: afatinib

First Posted Date: 2021-03-12

Last Posted Date: 2024-12-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 805

Registration Number: NCT04795245

Locations: 🇯🇵
Nippon Boehringer Ingelheim Co., Ltd., Tokyo, Japan

A Study in Healthy Men to Test How BI 1595043 is Taken up in the Body When Given With or Without Food

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1595043

First Posted Date: 2021-03-09

Last Posted Date: 2024-02-22

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 13

Registration Number: NCT04789291

Locations: 🇧🇪
SGS Life Science Services - Clinical Research, Edegem, Belgium

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy